Argenx is stopping a global clinical trial testing its drug efgartigimod against a placebo in adults with moderate to severe Sjögren’s disease after an independent analysis deemed the study unlikely to meet its main goal. Based on a predefined interim analysis of the trial’s data, an independent data…
Discussion
Add-on treatment with Artiva Biotherapeutics’ experimental cell therapy AlloNK (AB-101) was associated with improvements in symptoms and increased saliva flow at six months in a small group of adults with difficult-to-treat Sjögren’s disease in a basket clinical trial. However, the global Phase 2a study (NCT06991114) is a…
Discussion
Amgen’s experimental therapy dazodalibep led to rapid, sustained reductions in disease activity among adults with moderate-to-severe Sjögren’s disease in a global clinical trial, according to top-line data announced by the company. “The results mark an important step forward for people living with Sjögren’s disease, a condition with significant…
Discussion
Swelling of the major salivary glands without dry mouth at the time of a Sjögren’s disease diagnosis may point to a distinct disease profile marked by younger age, higher disease activity, and more severe glandular abnormalities, a study from South Korea suggested. “Recognition of this [Sjögren’s] presentation may support…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
